氨甲环酸联合地塞米松在腹腔镜子宫肌瘤剔除术中的随机对照试验
该前瞻性随机双盲安慰剂对照试验纳入100例子宫肌瘤患者,比较静脉氨甲环酸1g与安慰剂(均联合肌层内地塞米松)在腹腔镜子宫肌瘤剔除术中的效果。结果显示两组估计失血量中位数(150 mL vs 100 mL)及输血率(10% vs 6%)无显著差异,氨甲环酸安全但未显著减少失血或输血需求。
要点
- 氨甲环酸未显著降低腹腔镜子宫肌瘤剔除术的估计失血量或输血率。
- 肌瘤数目和直径是失血量的独立预测因素。
- 年龄增加与输血风险独立相关(OR 1.18)。
核心结论
- 与安慰剂相比,静脉氨甲环酸安全但未显著减少估计失血量或输血需求;不推荐常规联合使用,但高肌瘤负荷患者可能需进一步评估。
研究设计与样本
- 前瞻性、随机、双盲、安慰剂对照试验,纳入100例行腹腔镜子宫肌瘤剔除术的症状性子宫肌瘤女性,随机接受静脉氨甲环酸1g(n=50)或安慰剂(生理盐水;n=50),所有患者均接受肌层内地塞米松30 mcg(溶于100 mL生理盐水)。
主要发现
- 氨甲环酸组与安慰剂组估计失血量中位数无显著差异(150 mL vs 100 mL;p = .269)。
- 输血率相似(10% vs 6%;p = .715)。
- 术后血红蛋白水平两组相当(p = .505)。
- 第一组手术难度评分显著高于第二组(中位评分:6 vs 5,p = .016)。
- 多变量回归显示肌瘤数目(B = 19.09 mL/个;95%CI:8.31-29.86;p = .001)和肌瘤直径(B = 2.02 mL/cm;95%CI:0.18-3.85;p = .032)是失血的独立预测因素;年龄增加与输血风险独立相关(OR 1.18;95%CI:1.00-1.38;p = .044)。
关键数值与推荐
- 排除 suspected malignancy、血栓栓塞性疾病、严重系统性疾病、凝血异常、抗凝药物使用、BMI ≥30 kg/m²或合并其他手术的患者。
临床怎么用
- 不推荐在腹腔镜子宫肌瘤剔除术中常规联合使用静脉氨甲环酸和肌层内地塞米松以降低失血。
- 对于肌瘤数目多或直径大的患者,可考虑进一步评估氨甲环酸的效果。
局限性
- 样本量较小(100例),可能不足以检测出血量的微小差异。
- 研究排除了BMI≥30 kg/m²、凝血异常等特定人群,结果外推受限。
- 手术难度评分在组间存在显著差异,可能影响失血量的比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether intravenous tranexamic acid combined with intramyometrial desmopressin reduces perioperative blood loss during laparoscopic myomectomy. DESIGN: A prospective, randomized, double-blind, placebo-controlled trial. SETTING: A tertiary university hospital. PATIENTS: One hundred women undergoing laparoscopic myomectomy for symptomatic uterine fibroids were included in the study. Patients with suspected malignancy, thromboembolic disease, significant systemic illness, abnormal coagulation, anticoagulant use, body mass index ≥30 kg/m², or concomitant surgical procedures were excluded. INTERVENTIONS: Participants were randomized to receive intravenous tranexamic acid 1 g (n = 50) or placebo (normal saline; n = 50). All patients received intramyometrial desmopressin (30 mcg diluted in 100 mL normal saline). MEASUREMENTS AND MAIN RESULTS: Median estimated blood loss did not differ significantly between the tranexamic acid and placebo groups (150 mL vs 100 mL; p = .269). Transfusion rates were similar (10% vs 6%; p = .715). Postoperative hemoglobin levels were comparable between groups (p = .505). Surgeon-rated operative difficulty scores were significantly higher in Group I than in Group II (median score: 6 vs 5, p = .016). Multivariable regression identified myoma number (B = 19.09 mL per myoma; 95% CI: 8.31-29.86; p = .001) and myoma diameter (B = 2.02 mL per cm; 95% CI: 0.18-3.85; p = .032) as independent predictors of blood loss. Increasing age was independently associated with blood transfusion risk (odds ratio 1.18; 95% CI: 1.00-1.38; p = .044). CONCLUSION: Tranexamic acid was safe but did not significantly reduce estimated blood loss or the need for transfusion compared with the placebo. Routine combined use is not supported; however, further evaluation in patients with a higher myoma burden may be warranted.
引用
- Ozbasli E, Unsal G, Dede FS, et al. Intravenous Tranexamic Acid Combined With Intramyometrial Desmopressin During Laparoscopic Myomectomy: A Randomized Double-Blind Placebo-Controlled Trial. J Minim Invasive Gynecol. 2026. PMID: 41932577. doi:10.1016/j.jmig.2026.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。